Study: NCT05000216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MTX)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (B cell depletion therapy)
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (B cell depletion therapy)
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (B cell depletion therapy)
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (B cell depletion therapy)
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (B cell depletion therapy)
Description: Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.